Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868722 | 0.82 | RIPK1 (0.35) | RAB9ANPC1L3MBTL1ALDH1A1HPGD | |
| SCHEMBL14868723 | 0.80 | ALOX5 (0.38) | RAB9ANPC1L3MBTL1ALDH1A1HPGD | |
| SCHEMBL24433696 | 0.73 | SMN1; SMN2 (0.32) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL14868664 | 0.72 | ALOX5 (0.39) | RAB9ANPC1L3MBTL1ALDH1A1HPGD | |
| SCHEMBL14868666 | 0.71 | ADRA2A (0.38) | RAB9ANPC1L3MBTL1ALDH1A1RIPK1 | |
| SCHEMBL6659364 | 0.70 | TAAR1 (0.45) | RAB9ANPC1L3MBTL1ALDH1A1HPGD | |
| Iodide SCHEMBL27926075 | 0.69 | TAAR1 (0.43) | RAB9ANPC1L3MBTL1ALDH1A1HPGD | |
| SCHEMBL14868721 | 0.69 | RAB9A (0.46) | RAB9ANPC1L3MBTL1ALDH1A1HPGD | |
| SCHEMBL14868665 | 0.69 | RAB9A (0.46) | RAB9ANPC1L3MBTL1ALDH1A1POLB | |
| SCHEMBL1025241 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | RAB9A 2425/4885NPC1 405/4885L3MBTL1 4566/4885 |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | RAB9A 2425/4885NPC1 405/4885L3MBTL1 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.